About CHA₂DS₂-VASc
The CHA₂DS₂-VASc score quantifies stroke risk in patients with non-valvular atrial fibrillation to guide anticoagulation decisions. Introduced by Lip et al. in 2010 as a refinement of the original CHADS₂ score, it adds vascular disease, age 65–74, and sex category to improve risk stratification in low-risk patients. The score is the cornerstone of AFib management guidelines worldwide and is recommended by the ACC/AHA, ESC, and CCS.
Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting approximately 2–4% of the US population and up to 10% of adults over 80. It is a major independent risk factor for ischemic stroke, increasing stroke risk by approximately 5-fold. Without anticoagulation, AFib patients have a stroke rate of approximately 5% per year overall — but risk varies dramatically by CHA₂DS₂-VASc score from <1% to >15% annually.
How to Use This Calculator
Check each risk factor that applies to the patient. The calculator sums the points in real time and displays the total score, estimated annual stroke risk, and anticoagulation recommendation. Note that the Age ≥75 and Age 65–74 checkboxes are mutually exclusive — checking Age ≥75 will automatically uncheck Age 65–74.
Pay attention to the female sex note: if the only checked box is female sex (score = 1), the calculator will flag that anticoagulation is NOT recommended in this case. Anticoagulation benefit in women requires at least one additional non-sex risk factor.
Acronym Breakdown
| Letter | Risk Factor | Points |
|---|---|---|
| C | Congestive heart failure / LV dysfunction (LVEF <40%) | 1 |
| H | Hypertension (BP >140/90 on ≥2 occasions, or on antihypertensives) | 1 |
| A₂ | Age ≥75 years (double weight — highest single risk factor) | 2 |
| D | Diabetes mellitus (fasting glucose >125 mg/dL, or on antidiabetics) | 1 |
| S₂ | Stroke / TIA / systemic thromboembolism history (double weight) | 2 |
| V | Vascular disease (prior MI, peripheral artery disease, or aortic plaque) | 1 |
| A | Age 65–74 years (not combinable with A₂) | 1 |
| Sc | Sex category (female) — modifier, not independent risk factor | 1 |
Interpretation Guide: Annual Stroke Risk by Score
| Score | Annual Stroke Risk | Anticoagulation Recommendation | Guideline Class |
|---|---|---|---|
| 0 (men) / 1 (women, sex only) | 0.0–0.5% | No anticoagulation | Class III (No Benefit) |
| 1 (men) / 2 (women) | 1.3% | May consider OAC (shared decision) | Class IIb |
| 2 (men) / 3 (women) | 2.2% | Oral anticoagulation recommended | Class I |
| 3 | 3.2% | Oral anticoagulation recommended | Class I |
| 4 | 4.0% | Oral anticoagulation recommended | Class I |
| 5 | 6.7% | Oral anticoagulation recommended | Class I |
| 6 | 9.8% | Oral anticoagulation recommended | Class I |
| 7 | 9.6% | Oral anticoagulation recommended | Class I |
| 8 | 6.7% | Oral anticoagulation recommended | Class I |
| 9 | 15.2% | Oral anticoagulation recommended | Class I |
Annual stroke risk estimates per Lip GYH 2010 cohort study. Class designations per 2023 ACC/AHA AFib Guidelines.
Note on Female Sex as a Risk Modifier
Female sex alone (CHA₂DS₂-VASc = 1 in a patient with no other risk factors) is not considered a net benefit indication for anticoagulation. The 2023 AHA/ACC guidelines clarify that female sex is a risk modifier, not an independent risk factor. Anticoagulation should be considered when there is ≥1 additional non-sex-based risk factor. This distinction is critically important — a 65-year-old woman with AFib but no other risk factors (CHA₂DS₂-VASc = 1) has similar absolute stroke risk to a 64-year-old man with no risk factors (score = 0), and neither benefits from anticoagulation in the absence of additional risk factors.
DOAC Selection for Non-Valvular AFib
When anticoagulation is indicated, direct oral anticoagulants (DOACs) are preferred over warfarin for non-valvular AFib unless contraindicated. All four approved DOACs have demonstrated non-inferiority or superiority to warfarin for stroke prevention with lower rates of intracranial hemorrhage:
- Apixaban (Eliquis): 5 mg BID (2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL). Demonstrated reduction in stroke and all-cause mortality vs. warfarin in ARISTOTLE trial.
- Rivaroxaban (Xarelto): 20 mg daily with evening meal. Once-daily dosing may improve adherence. ROCKET-AF trial.
- Dabigatran (Pradaxa): 150 mg BID (75 mg BID for CrCl 15–30). Reversal agent (idarucizumab) available. RE-LY trial.
- Edoxaban (Savaysa): 60 mg daily (30 mg if CrCl 15–50, weight ≤60 kg, or P-gp inhibitors). ENGAGE AF-TIMI 48 trial.
DOACs are contraindicated in: mechanical heart valves and moderate-to-severe rheumatic mitral stenosis (use warfarin target INR 2.5–3.5). Renal function must be checked before initiating any DOAC and monitored periodically.
Limitations and Considerations
CHA₂DS₂-VASc has important limitations that must be understood:
- Non-valvular AFib only. The score applies to non-valvular AFib. Patients with mechanical heart valves or moderate-severe rheumatic mitral stenosis require anticoagulation regardless of score.
- Bleeding risk not included. CHA₂DS₂-VASc does not incorporate bleeding risk. The HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly >65, Drugs/alcohol) should be assessed alongside CHA₂DS₂-VASc to evaluate net clinical benefit.
- Annual risk estimates are population averages. Individual risk is affected by factors beyond the score including AFib burden, rate vs. rhythm control, blood pressure control, and comorbidities.
- Does not apply to atrial flutter. While atrial flutter carries similar stroke risk, it is less studied. Many guidelines recommend treating flutter similarly to AFib regarding anticoagulation.
References
Lip GYH, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest. 2010;137(2):263–272.
Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation. J Am Coll Cardiol. 2024;83(1):109–279.
Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373–498.
Granger CB, et al. (ARISTOTLE Trial). Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.